News und Analysen
![True Leaf meldet Zustimmung der Gläubiger zu den Vorschlägen](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
True Leaf meldet Zustimmung der Gläubiger zu den Vorschlägen
Das Unternehmen erreicht einen wichtigen Schritt für den Ausstieg aus dem Gläubigerschutz und die Unternehmensumstrukturierung
Vernon (British Columbia), 23. Oktober 2020. True Leaf
![BB Biotech: Ein drittes Quartal zum Abhaken](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
BB Biotech: Ein drittes Quartal zum Abhaken
BB Biotech (WKN: A0NFN3) legte heute seinen Quartalsbericht vor und informierte zugleich über „erhöhte Übernahmeaktivitäten“ im Pharmasektor, aus denen die Investmentgesellschaft selbst Kapital
PerkinElmer Board Declares Quarterly Dividend
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock October 22, 2020. This dividend is payable on February 12, 2021 to
![Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeThpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5d91333dbb55b274fa0400e435af0453aa80c824/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aurinia-logo-web-700px.jpg?locale=de)
Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications
![Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN29sRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2c39f3b6129a12541932c63b90c23307b141ad6b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/puma_logo_JPEG.jpg?locale=de)
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, Nov. 5, 2020, following the release of its third
![Humana, Quantified Ventures, and Volunteers of America Partner to Establish First of Its Kind Health Outcomes Fund: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaXNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3d3c39355769d1759c5221ae0bf511106538ecb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Humana_logo.png?locale=de)
Humana, Quantified Ventures, and Volunteers of America Partner to Establish First of Its Kind Health Outcomes Fund
Humana Inc. (NYSE: HUM) today re-confirms its commitment to provide innovative models of care for families through a catalytic investment of $5 million in an outcomes-based fund, supported by
![BOIRON : Activity in the third quarter of 2020](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
BOIRON : Activity in the third quarter of 2020
October 22, 2020
ACTIVITY IN THE THIRD QUARTER OF 2020
(Unaudited data)
Cumulative activity as of the end of september 2020
In thousands of euros 2020 2019 Variation at current exchange![Navidea Biopharmaceuticals to Present at the Virtual Investor KOL Roundtable: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNllsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8f98c3cfd17bc93aed823f932a665c78f3f036eb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/navidea_cmyk.jpg?locale=de)
Navidea Biopharmaceuticals to Present at the Virtual Investor KOL Roundtable
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
![Lantheus Holdings to Host Third Quarter 2020 Earnings Conference Call and Webcast on November 5, 2020 at 8:00 a.m. Eastern Time](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Lantheus Holdings to Host Third Quarter 2020 Earnings Conference Call and Webcast on November 5, 2020 at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 5, 2020, to discuss its financial and
![Therma Bright and Orpheus Medica Advance CoviSafe™ Rapid Saliva Test to Formal Product Developmental Phase](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Therma Bright and Orpheus Medica Advance CoviSafe™ Rapid Saliva Test to Formal Product Developmental Phase
- Successful Completion of the feasibility Studies followed by engagement of nanoComposix to accelerate the development of CoviSafe™
Toronto, Ontario--(October 21, 2020) –
![Therma Bright und Orpheus Medica überführen den Speichel-Schnelltest CoviSafe™ in die formelle Produktentwicklungsphase](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Therma Bright und Orpheus Medica überführen den Speichel-Schnelltest CoviSafe™ in die formelle Produktentwicklungsphase
- Erfolgreicher Abschluss der Machbarkeitsstudien, gefolgt von der Beauftragung von nanoComposix zur beschleunigten Entwicklung von CoviSafe™
Toronto, Ontario--(21. Oktober 2020)
![University Medical Center and Humana Sign Agreement, Expanding Humana’s Medicare Advantage Provider Network in New Orleans : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaXNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3d3c39355769d1759c5221ae0bf511106538ecb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Humana_logo.png?locale=de)
University Medical Center and Humana Sign Agreement, Expanding Humana’s Medicare Advantage Provider Network in New Orleans
University Medical Center New Orleans, a part of LCMC Health, and Humana Inc. (NYSE: HUM), a leading health and well-being company, have signed an in-network agreement, expanding access to care for
![Humana Joins Forces with DAV (Disabled American Veterans): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaXNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3d3c39355769d1759c5221ae0bf511106538ecb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Humana_logo.png?locale=de)
Humana Joins Forces with DAV (Disabled American Veterans)
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, has entered into an agreement with DAV (Disabled American Veterans), an organization whose mission is
![Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020
Pfizer Inc. (NYSE:PFE) today announced the full analysis from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine
![CO.DON AG: Prognose für 2020 bestätigt](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
CO.DON AG: Prognose für 2020 bestätigt
- Leichtes Wachstum trotz Pandemie-Einflüssen
- Weiterhin Wachstum im Gesamtjahresverlauf erwartet
Berlin / Teltow / Leipzig, 21.10.2020 – Die CO.DON AG wird trotz der
![STAAR Surgical to Report Third Quarter Results on November 4, 2020: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd2MrTHc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ea827a8a18ac48b4411e5b4a6acd688cf767d614/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/STAAR_Surgical_Logo_Primary_Lockup_-28Sunise_Teal-29.jpg?locale=de)
STAAR Surgical to Report Third Quarter Results on November 4, 2020
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release
![Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTRqRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8c255f1cb7b73806f677f1d1d64e93866d2979a5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Clovis_Logo_Process_Color.jpg?locale=de)
Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management
![Simulations Plus Releases GastroPlus® Version 9.8: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNEFWS2c9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ff1977c5f19c19899ef789fb8e692387f41c81f2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/BusinessWireLogo.jpg?locale=de)
Simulations Plus Releases GastroPlus® Version 9.8
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that
![Chief Medical Officers from Boston Scientific, Illumina, Johnson & Johnson, and QIAGEN to Keynote Veeva MedTech Summit Online](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Chief Medical Officers from Boston Scientific, Illumina, Johnson & Johnson, and QIAGEN to Keynote Veeva MedTech Summit Online
Veeva Systems (NYSE: VEEV) today announced the featured keynote speakers at 2020 Veeva Medical Device & Diagnostics Summit Online. Chief medical officers from Boston Scientific, Illumina, Johnson &
![Sartorius: Wie hoch denn noch?](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Sartorius: Wie hoch denn noch?
Wussten Sie eigentlich, dass auch Sartorius (WKN: 716563) zu den Überlebenden des Neuen Marktes zählt? Wenn nicht, dürften Sie sich in guter Gesellschaft befinden.
Denn selbst diejenigen, die
![NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25oRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fb25377a8ea9e69d3b62f03b482ed70fb95efba1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LOGO_NANO_EXPANDING_LIFE.jpg?locale=de)
NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
![Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus : https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005725/en/
Vifor Pharma and Cara Therapeutics, Inc
![Quidel to Hold Third Fiscal Quarter 2020 Financial Results Conference Call on October 29th, 2020](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Quidel to Hold Third Fiscal Quarter 2020 Financial Results Conference Call on October 29th, 2020
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report third fiscal quarter 2020 financial
![Medigene AG: Medigene und Cytovant schließen Servicevertrag zur Entwicklung eines Herstellungsverfahrens für DC-Impfstoffe ab](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Medigene AG: Medigene und Cytovant schließen Servicevertrag zur Entwicklung eines Herstellungsverfahrens für DC-Impfstoffe ab
Planegg/Martinsried (19.10.2020) - Medigene AG (Medigene, FWB: MDG1, Prime Standard), ein Immunonkologie-Unternehmen mit klinischen Projekten fokussiert auf die Entwicklung